Navigation Links
Acclarent, Inc. Awarded 'Red Herring 100 North America'
Date:5/28/2009

MENLO PARK, Calif., May 29 /PRNewswire/ -- Acclarent, Inc., a leading medical technology company dedicated to designing, developing and commercializing devices that address conditions affecting the ear, nose and throat today announced that it won the "Red Herring 100 North America" award. The Red Herring editorial team deploys a detailed process to whittle down a pool of 1,200 eligible, promising companies to decide on the top 100 winners of this important North American award. Evaluations are made on both quantitative and qualitative criteria, such as financial performance, innovation, management, global strategy, and ecosystem integration. Alex Vieux, CEO of Red Herring, presented the award to the winning companies in San Diego on May 14, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090529/LA24185LOGO)

"Acclarent will cure and help millions of Americans over the years. This represents innovation excellence at its best led by pristine investors and a seasoned team. It fully deserves its place within the Red Herring 100 North America," said Mr. Vieux.

"Being recognized by Red Herring as one of the most promising private companies in North America is a tremendous accomplishment. On behalf of the 300 deserving employees at Acclarent, I would like to thank Red Herring for this prestigious award," said Bill Facteau, President and CEO of Acclarent, Inc.

About Red Herring

Red Herring is a global media company, which unites the world's best high technology innovators, venture investors and business decision makers in a variety of forums: a leading innovation magazine, an online daily technology news service, technology newsletters and major events for technology leaders around the globe. Red Herring provides an insider's access to the global innovation economy, featuring unparalleled insights on the emerging technologies driving the economy. More information about Red Herring is available online at www.redherring.com.

About Acclarent

Acclarent is a medical technology company dedicated to the development of innovative products providing new technologies to further meet the needs of ENT patients.

Acclarent's initial focus is on achieving the goals of sinus surgery with novel, endoscopic, catheter-based tools - Balloon Sinuplasty(TM) devices. Through the Balloon Sinuplasty(TM) technology and our Relieva(R) product portfolio we offer ENT patients alternatives to conventional endoscopic surgical approaches. Through our core technologies and commitment to innovation, Acclarent will continue to advance novel devices in all areas of ENT. Acclarent markets and sells its products worldwide and has been used by thousands of physicians globally. For more information about Acclarent, visit www.Acclarent.com.


'/>"/>
SOURCE Red Herring
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Acclarent, Inc. Granted Key Patent Covering Balloon Sinuplasty(TM) Technologies
2. Acclarent, Inc. Closes $26 Million Financing
3. Concurrent Technologies Corporation Awarded Contract to Support the Centers for Disease Control and Prevention with Readiness Efforts
4. Falcon Genomics Awarded Patent for Innovative Cancer Test
5. $18 million awarded to TGen and University of Pennsylvania for pancreatic cancer research
6. MHA Clinical Director Kimberly Binaso, Pharm.D. Awarded 2009 ASHP Fellow
7. University of Haifa research team awarded European Union research grant
8. $1.5 million awarded for palliative care research to improve care of seriously ill patients
9. NCQA Accreditation Status of Excellence Awarded to Blue Cross and Blue Shield of Georgia
10. MiP Consortium awarded €11 million by EDCTP
11. American Cancer Society Awarded Dual WellPoint Foundation Grants to Expand Hope Lodge Network and Patient Navigation Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... Groth Family ... Pasco and Richland, is initiating a charity drive to support the family of ... recent automobile collision. , On October 29th of this year, Cindy Hendrickson ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... its 10th anniversary with the grand opening of the Sober College Robert Pfeifer ... spanned two days, December 2-3, and was attended by an overwhelming amount of ...
(Date:12/9/2016)... ... December 09, 2016 , ... "I had a terrible time trying to get ... thought that if the nebulizer had a more child-friendly design, then children would be ... developed the patent-pending NEBY to avoid the need to deliver medication via a nebulizer ...
(Date:12/8/2016)... Pennsylvania (PRWEB) , ... December 08, 2016 , ... ... Duck Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which ... , “This was our first franchise-wide Quack Gives Back initiative, ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, the ... (WIYM) campaign to inform dentists and patients about the safety issues related to dental ... market in the U.S. is projected to reach $6.4 billion in 2018 with more ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... 2016  Axovant Sciences Ltd. (NYSE: ... on the treatment of dementia, today announced a ... 2b trial evaluating treatment with intepirdine (RVT-101), combined ... plus placebo in people with mild-to-moderate Alzheimer,s disease. ... to treatment was associated with reduced progression in ...
(Date:12/8/2016)... LONDON , Dec. 8, 2016 Australia ... GlobalData,s new report, "Australia Ophthalmic Lasers Market Outlook to ... Lasers market. The report provides value, in millions of ... within market segements - Excimer Lasers, Femtosecond Lasers and ... and distribution shares data for each of these market ...
(Date:12/8/2016)... 2016  The global biosurgery market is expected to ... period of 2016 to 2021. The market is poised ... 18.21 billion in 2016. The market is primarily driven ... related injuries and spinal problems, increasing clearance of biosurgery ... blood loss management. In this report, the ...
Breaking Medicine Technology: